Bayer: Science For A Better Life

United States of America

Radiology Information for Grant Submissions

Bayer Radiology Medical Affairs Department is interested in receiving and reviewing Grant Applications to support appropriate programs as described below.

Therapeutic Areas/Disease States:


Intended Audience: Radiologists, MRI Technologists, Referring Physicians, MRI Nurses, Pharmacists.

Bayer Radiology Rationale for Educational Support:

Areas of interest based on referenced literature:

  • Gadavist-enhanced MRI applications and protocols
  • Pediatric applications and protocols for Gadavist-enhanced MRI
  • Physiologic understanding of gadolinium and its properties
  • Radiation and contrast dose monitoring and optimization
  • Optimum protocols for power injector use in CT and MRI
  • Injector use in PET
  • Patient education and understanding such as breast MRI

Accredited Proposal Requirements:

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).

The proposal should include:

  • Needs Assessment
  • Educational Design and Rationale for Selection
  • Learning Objectives
  • Proposed Faculty
  • Participant Recruitment Plan
  • Outcomes Strategy/plan
  • Definition of Successful Program
  • Detailed Budget (must use the template available on the website)

Provider Justification:

  1. Copy of most recent accreditation letter and status
  2. Samples of other programs in similar therapeutic areas


Applications/proposals which are submitted and determined to be complete are reviewed monthly.

Acceptance of a Bayer educational grant indicates that you will:

  • Reconcile grant funding within 60 days of completion of the educational program
  • Permit a Bayer Medical Affairs representative to audit live programs of at least $5000 (Bayer Compliance staff may also audit live programs and/or review the use of the grant)
  • Share activity data and outcomes metrics within 30 days of their availability

Literature/Data Referenced

  1. Abujudeh HH, Dosaraju, VK, Kaewlai R, Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections, AJR AM J Roentgenol. 2010 Feb; 194(2); 430-434.
  2. Altun E, Martin DR, Wertman R, et al. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy-report from two US universities. Radiology. 2009 Dec; 253(3):689-696. Epub 2009 Sept 29.
  3. Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol. 2008 May; 66(2):160-167. Epub 2008 Mar20.Review.
  4. Forsting M, Palkowitsch P. Prevalence of acute adverse reactions to gadobutrol-a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials. Eur J Radiol. 2010 Jun; 74(3):e186-192. Epub 2009 Jul2.
  5. Ge Y, Multiple sclerosis: the role of MR imaging, AJNR Am J Neuroradiol, 2006; 27: 1165-76.
  6. Kurtkoti, J., et al. Gadolinium and Nephrogenic Systemic Fibrosis: Association or Causation, Nephrology June 2008;13: 235-41.
  7. Lin SP, Brown JJ. MR contrast agents. Physical and pharmacologic basics. J Magn Reson Imaging. 2007; 25:884-899 Abstract.
  8. Morcos SK. Extracellular gadolinium contrast agents: difference in stability. Eur J Radiol. 2008 May;66(2): 175-179. Epub 2008 Mar14.
  9. Provenzale JM, Mukundan S, Barboriak DP. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology. 2006 Jun;239(3):632-49. (2006) Abstract.
  10. ACR Practice Guideline for Performing and Interpreting Magnetic Resonance Imaging (MRI)., Available at the American College of Radiology web site: Manual/FullManual.pdf.